Translational Medicine Research Center, China Medical University Hospital, Taichung 404, Taiwan.
Department of Biochemistry, School of Medicine, Chang-Gung University, Taoyuan 333, Taiwan.
Cells. 2020 Jun 20;9(6):1504. doi: 10.3390/cells9061504.
Long intergenic non-coding RNAs (lincRNAs) play important roles in human cancer development, including cell differentiation, apoptosis, and tumor progression. However, their underlying mechanisms of action are largely unknown at present. In this study, we focused on a novel suppressor lincRNA that has the potential to inhibit progression of human hepatocellular carcinoma (HCC). Our experiments disclosed long intergenic non-protein coding RNA 1488 (LINC01488) as a key negative regulator of HCC. Clinically, patients with high LINC01488 expression displayed greater survival rates and better prognosis. In vitro and in vivo functional assays showed that LINC01488 overexpression leads to significant suppression of cell proliferation and metastasis in HCC. Furthermore, LINC01488 bound to cyclin E to induce its ubiquitination and reduced expression of vimentin mediated by both miR-124-3p/miR-138-5p. Our results collectively indicate that LINC01488 acts as a tumor suppressor that inhibits metastasis and tumorigenesis in HCC via the miR-124-3p/miR-138-5p/vimentin axis. Furthermore, LINC01488 interacts with and degrades cyclin E, which contributes to its anti-tumorigenic activity. In view of these findings, we propose that enhancement of LINC01488 expression could be effective as a potential therapeutic strategy for HCC.
长链非编码 RNA(lncRNAs)在人类癌症发展中发挥重要作用,包括细胞分化、凋亡和肿瘤进展。然而,它们的作用机制目前在很大程度上尚不清楚。在本研究中,我们专注于一种新型抑制 lincRNA,它有可能抑制人肝细胞癌(HCC)的进展。我们的实验揭示了长链非蛋白编码 RNA 1488(LINC01488)是 HCC 的关键负调控因子。临床上,LINC01488 高表达的患者具有更高的生存率和更好的预后。体外和体内功能试验表明,LINC01488 过表达导致 HCC 细胞增殖和转移的显著抑制。此外,LINC01488 与细胞周期蛋白 E 结合,诱导其泛素化,并降低 miR-124-3p/miR-138-5p 介导的波形蛋白的表达。我们的研究结果表明,LINC01488 作为一种肿瘤抑制因子,通过 miR-124-3p/miR-138-5p/波形蛋白轴抑制 HCC 的转移和肿瘤发生。此外,LINC01488 与 cyclin E 相互作用并使其降解,这有助于其抗肿瘤活性。鉴于这些发现,我们提出增强 LINC01488 的表达可能是 HCC 的一种潜在治疗策略。